


The Molecular Screening and Therapeutics in Leukaemia and Lymphoma Study (MoST-LLy) General Information Sheet

Chief Investigator	Prof Steven Lane (Clinical Lead)
Clinical Trials Project Managers	Gerlinda Amor, Helen Christensen
Contact details for queries:	Phone: (07) 3845 3766 or 0487 400 607 Email: mostlly@qimrb.edu.au

What is the MoST-LLy Study?

The fundamental premise of the MoST-LLy study is that innovations in genetic screening of blood cancers are needed to expedite translation of discovery into improved health outcomes for patients. The MoST-LLy study is testing a new approach to genetic screening of patients with blood cancer and reviewing eligibility for new treatments where possible.



If a patient is suitable for the MoST-LLy study, and consents to participate, their blood cancer is tested to see if their DNA contains genetic biomarkers that may guide treatment. This process is called molecular screening or comprehensive genetic panel (CPG) testing. After a patient's blood cancer is tested, a report is sent to the referring haematologist including:

- (i) Any genetic biomarkers that were identified in the blood cancer, and
- (ii) Any types of treatment that may be suitable (if found).

Who is suitable for the MoST-LLy Program?

Blood cancer patients 18 years and over, with advanced blood cancer of any type.

How can a patient enrol in the MoST-LLy Program?

A patient is asked to discuss the MoST-LLy study with their treating Haematologist.

Haematologist's can review eligibility criteria and refer potentially eligible patient's through a secure online MoST-LLy referral form with the patients medical history and a Pathology Report (to confirm the type of blood cancer and assist the study team to request a sample for testing).

If you are interested in the MoST-LLy study and would like a copy of the eligibility criteria or the MoST-LLy Referral form, please contact the Clinical Trial Project Managers, listed above, or refer to the website at: <https://www.qimrb.edu.au/studies/most-lly-study>

The ethical aspects of this study have been approved by the HREC of Metro South Health EC00167 (HREC/2024/QMS/113451).

This study is made possible through the support of the Leukaemia Foundation of Australia, Tour de Cure and an MRFF Grant with CIA Prof Steven Lane.